We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Cancer Immunology – News and Features

News

Engineered Virus Targets and Kills Apparent Cancer Stem Cells in Neuroblastoma

Treatment blocked deadly nerve cancer in study led by Cincinnati Children's Hospital Medical Center.
News

Angion Biomedica Signs Licensing Option with Memorial Sloan Kettering Cancer Center

Angion Biomedica licenses a vaccine platform that enables presentation of multiple carbohydrate antigens on a single synthetic scaffold.
News

Immutep Announces Positive Interim Results in Phase I/II Chemoimmunotherapy Trial in Breast Cancer

The ImmuFact IMP321 associated with paclitaxel shows double clinical response rate.
News

Advaxis’ Phase II Clinical Trial "HOLD" Lifted

The U.S. FDA approves investigational new drug application for Phase II for cervical intraepithelial Neoplasia grade 2/3 clinical trial.
News

ImmunoCellular Therapeutics’ Cancer Vaccine Demonstrates Immune Response against Brain Cancer in Clinical Trial

Company presents promising clinical data from a Phase I trial evaluating dendritic cell-based cancer vaccine for the treatment of glioblastoma.
News

Cell Genesys and Takeda Announce Termination of Collaboration Agreement for GVAX Immunotherapy for Prostate Cancer

Both companies have mutually agreed to suspend the collaboration agreement for the development and commercialization of the product.
News

Geron Announces Initiation of Phase I Clinical Trial of Vaccine Candidate Targeting Telomerase by Merck

The trial will assess the safety, tolerability and immunogenicity of the non-dendritic cell based cancer vaccine in patients with solid tumors.
News

Vical Receives Milestone Payment from Merck Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial

Vical announces receipt of a $1.0 million milestone based on Merck's planned initiation of a Phase I clinical trial of pDNA cancer vaccine.
News

Celldex Announces Licensing Agreement for Cancer Antibody Program

Celldex enters an exclusive patent and know-how license agreement with the University of Southampton, UK, to develop human antibodies towards CD27.
News

Canopus BioPharma Announces Positive Results in Human Study of Peptide Cancer Vaccine

Study analyzed at Southern Research Institute shows human antibodies generated by Canopus’s peptides have anti-cancer properties.
Advertisement